Protalix BioTherapeutics Reveals PRX-115 Phase I Clinical Trial Data Presentation at ACR Convergence 2024

Protalix BioTherapeutics Inc. recently unveiled significant developments regarding its recombinant PEGylated uricase product, PRX-115. The company announced that data from the phase I clinical trial of PRX-115, aimed at treating uncontrolled gout, will be presented in a late-breaking poster at the American College of Rheumatology (ACR) Convergence 2024. The event is scheduled from November 14 to 19, 2024, at the Walter E. Washington Convention Center in Washington, D.C.

A press release issued by Protalix BioTherapeutics on October 25, 2024, highlighted the forthcoming presentation and mentioned that interested individuals can access an abstract, with trial data, on the ACR Convergence 2024 website at https://acrabstracts.org/abstract/prolonged-plasma-urate-lowering-after-a-single-intravenous-administration-of-prx-115-a-novel-pegylated-uricase-in-participants-with-elevated-urate-levels/. The full press release is provided as Exhibit 99.1 with the Current Report on Form 8-K.

As per General Instruction B.2 of Form 8-K, the data shared in this report, including Exhibit 99.1, is not considered “filed” under the Securities Exchange Act of 1934. Protalix BioTherapeutics clarified that this information, although significant, is not subject to the liabilities outlined in Section 18 of the Exchange Act and will not be incorporated by reference into any registration statement or document filed under the Securities Act of 1933 or the Exchange Act unless expressly specified.

In a separate statement, Protalix BioTherapeutics’ Dror Bashan, the President, and Chief Executive Officer, formally signed and submitted the report on behalf of the company on October 25, 2024.

This update from Protalix BioTherapeutics signifies a step forward in the development and potential commercialization of PRX-115 for the treatment of uncontrolled gout. The company continues to pursue advancements in biopharmaceuticals, with a focus on addressing unmet medical needs and enhancing patient care in various therapeutic areas.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Protalix BioTherapeutics’s 8K filing here.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.